-
1
-
-
1842844950
-
Consensus development conference on antipsychotic drugs and obesity and diabetes
-
American Diabetes Association, American Psychiatric AssociationAmerican Psychiatric Association, American Association of Clinical EndocrinologistsAmerican Association of Clinical Endocrinologists, North American Association for the Study of ObesityNorth American Association for the Study of Obesity
-
Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004, 65:267-272. American Diabetes Association, American Psychiatric AssociationAmerican Psychiatric Association, American Association of Clinical EndocrinologistsAmerican Association of Clinical Endocrinologists, North American Association for the Study of ObesityNorth American Association for the Study of Obesity.
-
(2004)
J Clin Psychiatry
, vol.65
, pp. 267-272
-
-
-
2
-
-
33846596713
-
Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients
-
Arranz B., San L., Duenas R.M., Centeno M., Ramirez N., Salavert J., et al. Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients. Hum Psychopharmacol Clin Exp 2007, 22:11-15.
-
(2007)
Hum Psychopharmacol Clin Exp
, vol.22
, pp. 11-15
-
-
Arranz, B.1
San, L.2
Duenas, R.M.3
Centeno, M.4
Ramirez, N.5
Salavert, J.6
-
3
-
-
77957129707
-
Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study
-
Bitter I., Treuer T., Dilbaz N., Oyffe I., Ciorabai E.M., Gonzalez S.L., et al. Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study. World J Biol Psychiatry 2010, 11:894-903.
-
(2010)
World J Biol Psychiatry
, vol.11
, pp. 894-903
-
-
Bitter, I.1
Treuer, T.2
Dilbaz, N.3
Oyffe, I.4
Ciorabai, E.M.5
Gonzalez, S.L.6
-
4
-
-
33846624634
-
Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS study
-
Bobes J., Arango C., Aranda P., Carmena R., Garcia-Garcia M., Rejas J., et al. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS study. Schizophr Res 2007, 90:162-173.
-
(2007)
Schizophr Res
, vol.90
, pp. 162-173
-
-
Bobes, J.1
Arango, C.2
Aranda, P.3
Carmena, R.4
Garcia-Garcia, M.5
Rejas, J.6
-
5
-
-
42549153837
-
Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial
-
Chawla B., Luxton-Andrew H. Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial. Hum Psychopharmacol Clin Exp 2008, 23:211-216.
-
(2008)
Hum Psychopharmacol Clin Exp
, vol.23
, pp. 211-216
-
-
Chawla, B.1
Luxton-Andrew, H.2
-
6
-
-
35348992825
-
Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets
-
Crocq M.-A., Guillon M.-S., Bailey P.E., Provost D. Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets. Eur Psychiatry 2007, 22:453-454.
-
(2007)
Eur Psychiatry
, vol.22
, pp. 453-454
-
-
Crocq, M.-A.1
Guillon, M.-S.2
Bailey, P.E.3
Provost, D.4
-
7
-
-
54849381700
-
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study
-
Daumit G.L., Goff D.C., Meyer J.M., Davis V.G., Nasrallah H.A., McEvoy J.P., et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 2008, 105:175-187.
-
(2008)
Schizophr Res
, vol.105
, pp. 175-187
-
-
Daumit, G.L.1
Goff, D.C.2
Meyer, J.M.3
Davis, V.G.4
Nasrallah, H.A.5
McEvoy, J.P.6
-
8
-
-
5444233534
-
Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets
-
De Haan L., van Amelsvoort T., Rosien K., Linszen D. Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology 2004, 175:389-390.
-
(2004)
Psychopharmacology
, vol.175
, pp. 389-390
-
-
De Haan, L.1
van Amelsvoort, T.2
Rosien, K.3
Linszen, D.4
-
9
-
-
60949099657
-
Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course
-
Gebhardt S., Haberhausen M., Heinzel-Gutenbrunner M., Gebhardt N., Remschmidt H., Krieg J.C., et al. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res 2009, 43:620-626.
-
(2009)
J Psychiatr Res
, vol.43
, pp. 620-626
-
-
Gebhardt, S.1
Haberhausen, M.2
Heinzel-Gutenbrunner, M.3
Gebhardt, N.4
Remschmidt, H.5
Krieg, J.C.6
-
10
-
-
42749096559
-
Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects
-
Graham K.A., Cho H., Brownley K.A., Harp J.B. Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects. Schizophr Res 2008, 101:287-294.
-
(2008)
Schizophr Res
, vol.101
, pp. 287-294
-
-
Graham, K.A.1
Cho, H.2
Brownley, K.A.3
Harp, J.B.4
-
11
-
-
0020535524
-
A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity
-
Hogan T.P., Awad A.G., Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983, 13:177-183.
-
(1983)
Psychol Med
, vol.13
, pp. 177-183
-
-
Hogan, T.P.1
Awad, A.G.2
Eastwood, R.3
-
12
-
-
47249148105
-
Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain
-
Karagianis J., Hoffmann V.P., Arranz B., Treuer T., Maguire G.A., De Haan L., et al. Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain. Hum Psychopharmacol Clin Exp 2008, 23:275-281.
-
(2008)
Hum Psychopharmacol Clin Exp
, vol.23
, pp. 275-281
-
-
Karagianis, J.1
Hoffmann, V.P.2
Arranz, B.3
Treuer, T.4
Maguire, G.A.5
De Haan, L.6
-
13
-
-
67650090764
-
A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: The PLATYPUS study
-
Karagianis J., Grossman L., Landry J., Reed V.A., de Haan L., Maguire G.A., et al. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: The PLATYPUS study. Schizophr Res 2009, 113:41-48.
-
(2009)
Schizophr Res
, vol.113
, pp. 41-48
-
-
Karagianis, J.1
Grossman, L.2
Landry, J.3
Reed, V.A.4
de Haan, L.5
Maguire, G.A.6
-
15
-
-
18844364769
-
Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders
-
Kinon B.J., Kaiser C.J., Ahmed S., Rotelli M.D., Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacology 2005, 25:255-258.
-
(2005)
J Clin Psychopharmacology
, vol.25
, pp. 255-258
-
-
Kinon, B.J.1
Kaiser, C.J.2
Ahmed, S.3
Rotelli, M.D.4
Kollack-Walker, S.5
-
16
-
-
0023244845
-
The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients
-
Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987, 334(Suppl):1-100.
-
(1987)
Acta Psychiatr Scand
, vol.334
, Issue.SUPPL
, pp. 1-100
-
-
Lingjaerde, O.1
Ahlfors, U.G.2
Bech, P.3
Dencker, S.J.4
Elgen, K.5
-
17
-
-
31344479789
-
Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers
-
Markowitz J.S., DeVane C.L., Malcolm R.J., Gefroh H.A., Wang J.-S., Zhu H.-J., et al. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J Clin Pharmacology 2006, 46:164-171.
-
(2006)
J Clin Pharmacology
, vol.46
, pp. 164-171
-
-
Markowitz, J.S.1
DeVane, C.L.2
Malcolm, R.J.3
Gefroh, H.A.4
Wang, J.-S.5
Zhu, H.-J.6
-
18
-
-
16644392426
-
Abnormalities of glucose metabolism associated with atypical antipsychotic drugs
-
Newcomer J.W. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004, 65(Suppl.18):36-46.
-
(2004)
J Clin Psychiatry
, vol.65
, Issue.SUPPL.18
, pp. 36-46
-
-
Newcomer, J.W.1
-
19
-
-
38349185038
-
Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol
-
Saddichha S., Ameen S., Akhtar S. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J Clin Psychopharmacol 2008, 28:27-31.
-
(2008)
J Clin Psychopharmacol
, vol.28
, pp. 27-31
-
-
Saddichha, S.1
Ameen, S.2
Akhtar, S.3
-
20
-
-
13544277253
-
-
Division of Mental Health and Protection of Substance Abuse. World Health Organization, Kanekoshobou, Tokyo, (in Japanese)
-
Tasaki M., Nakane M. WHO QOL 26 1997, Division of Mental Health and Protection of Substance Abuse. World Health Organization, Kanekoshobou, Tokyo, (in Japanese).
-
(1997)
WHO QOL 26
-
-
Tasaki, M.1
Nakane, M.2
-
21
-
-
77957874979
-
Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study
-
Vidarsdottir S., Vlug P., Roelfsema F., Froelich M., Pijl H. Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study. J Clin Psychiatry 2010, 71:1205-1211.
-
(2010)
J Clin Psychiatry
, vol.71
, pp. 1205-1211
-
-
Vidarsdottir, S.1
Vlug, P.2
Roelfsema, F.3
Froelich, M.4
Pijl, H.5
-
22
-
-
73949102385
-
Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets
-
Vidarsdottir S., Roelfsema F., Streefland T., Holst J.J., Rehfeld J.F., Pijl H. Short-term treatment with olanzapine does not modulate gut hormone secretion: olanzapine disintegrating versus standard tablets. Eur J Endocrinology 2010, 162:75-83.
-
(2010)
Eur J Endocrinology
, vol.162
, pp. 75-83
-
-
Vidarsdottir, S.1
Roelfsema, F.2
Streefland, T.3
Holst, J.J.4
Rehfeld, J.F.5
Pijl, H.6
-
23
-
-
0031775905
-
Development of the World Health Organization WHOQOL-BREF: quality of life assessment
-
WHO-QOL group
-
Development of the World Health Organization WHOQOL-BREF: quality of life assessment. Psychol Med 1998, 28:551-558. WHO-QOL group.
-
(1998)
Psychol Med
, vol.28
, pp. 551-558
-
-
|